2篇
您的检索式：作者名="Leeann Yao"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Organ preservation: from the past to the future显示文摘机关移植是为有结束阶段疾病的病人的最有效的治疗。保藏答案和技术在移植以后与病态和幸存有关直接为施主机关质量是关键的,它是。当前,静态的冷存储(SCS ) 是为机关保藏的标准方法。然而,当延长冷存储增加贡献长期的复杂并发症的早接枝机能障碍的风险,有 SCS 的保藏时间被限制。而且,对边缘的施主机关的使用的成长要求为机关评价和修理要求方法。机器灌注在机关保藏上整修了并且统治当前的研究。它被承认到它的动态性质和象生理一样环境。更复杂的机器灌注技术和更好的 perfusates 的发展可以导致机关修理 / 修理。这评论描述机关保藏的历史,总结迄今为止被做了的进步,并且讨论为机关保藏的未来方向。 | Lei JING Leeann YAO Michael ZHAO Li-ping PENG Mingyao LIU | 2018 | Acta Pharmacologica Sinica2018，39，5： | 11 |
| 2 | Applications and safety of gold nanoparticles as therapeutic devices in clinical trials显示文摘Use of gold nanoparticles(GNPs)in medicine is an emerging field of translational research with vast clinical implications and exciting therapeutic potential.However,the safety of using GNPs in human subjects is an important question that remains unanswered.This study reviews over 20 clinical trials focused on GNP safety and aims to summarize all the clinical studies,completed and ongoing,to identify whether GNPs are safe to use in humans as a therapeutic platform.In these studies,GNPs were implemented as drug delivery devices,for photothermal therapy,and utilized for their intrinsic therapeutic effects by various routes of delivery.These studies revealed no major safety concerns with the use of GNPs;however,the number of trials and total patient number remains limited.Multi-dose,multicenter blinded trials are required to deepen our understanding of the use of GNPs in clinical settings to facilitate translation of this novel,multifaceted therapeutic device.Expanding clinical trials will require collaboration between clinicians,scientists,and biotechnology companies. | Leeann Yao Dejan Bojic Mingyao Liu | 2023 | Journal of Pharmaceutical Analysis2023，13，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员